Walleye Capital’s Cidara Therapeutics CDTX Stock Holding History

Walleye Capital’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-91,000	Closed	-$20.1M	–	4455
2025 Q4	$20.1M	Buy	+91,000	New	+$14.7M	0.06%	294
2025 Q3	–	Sell	-5,900	Closed	-$287K	–	4557
2025 Q2	$287K	Buy	+5,900	New	+$142K	﹤0.01%	3078

Walleye Capital's CDTX Position: Q1 2026 in Review

Walleye Capital sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 91,000 shares — an estimated $20.1M sold.

Walleye Capital first reported a position in CDTX in Q2 2025 and held it in 2 quarters. The position peaked at $20.1M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Walleye Capital reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Walleye Capital sold 91,000 Cidara Therapeutics shares in Q1 2026, an estimated $20.1M.
Walleye Capital first reported a position in Cidara Therapeutics in Q2 2025 and held it in 2 quarters.
Walleye Capital's Cidara Therapeutics position peaked at $20.1M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.